Randomized, Placebo-Controlled Trial of K1 Acupoint Acustimulation to Prevent Cisplatin-Induced or Oxaliplatin-Induced Nausea

BACKGROUNDGreater than 70% of patients with cancer experience chemotherapy-induced nausea and vomiting. In the current study, the authors examined the effects of electrostimulation of the K1 acupoint located on the sole of the foot because it is believed to have the potential to control chemotherapy-induced nausea and vomiting. METHODSIn this trial, 103 patients diagnosed with primary or metastatic liver cancer were recruited before transcatheter arterial infusion (TAI) of cisplatin or oxaliplatin and randomized to either group A (51 patients who were treated with the antiemetic tropisetron and acustimulation at the K1 acupoint for 20 minutes approximately 1 to 2 hours before TAI on the first day and then daily for the subsequent 5 days) or group B (52 patients who were treated with tropisetron and electrostimulation at a placebo point on the heel). The rate, intensity, and duration of nausea and vomiting were collected at baseline and then daily for 5 days after TAI. Quality of life was assessed daily using the MD Anderson Symptom Inventory and the EuroQoL scale. RESULTSNo differences were found between groups A and B with regard to the incidence and degree of nausea or vomiting on day 1 or the following 5 days. Patients in group A had better EuroQoL scores compared with patients in group B (72.83 in group A vs 65.94 in group B; P =.04) on day 4 but not on the other days. No group differences were noted at any time point for MD Anderson Symptom Inventory scores. CONCLUSIONSElectrostimulation of K1 combined with antiemetics did not result in initial prevention of cisplatin-induced or oxaliplatin-induced nausea or vomiting. Cancer 2015;121:84-92. (c) 2014 American Cancer Society. This randomized, placebo-controlled trial investigated whether electrostimulation of acupoint K1 could control chemotherapy-induced nausea and vomiting among patients with primary or metastatic liver cancer. Electrostimulation of acupoint K1 did not appear to result in the prevention of acute or delayed cisplatin-induced or oxaliplatin-induced nausea or vomiting when combined with antiemetics.